A Randomised, Double Blind, Placebo-controlled, Parallel Group Trial of Low-dose Adjunctive alTeplase During prIMary PCI

Trial Profile

A Randomised, Double Blind, Placebo-controlled, Parallel Group Trial of Low-dose Adjunctive alTeplase During prIMary PCI

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 May 2018

At a glance

  • Drugs Alteplase (Primary)
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms T-TIME
  • Most Recent Events

    • 09 May 2018 Status changed from recruiting to active, no longer recruiting.
    • 12 Oct 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Jun 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top